Mass spectrometry protein tests: ready for prime time (or not)

References

• Tran JC, Zamdborg L, Ahlf DR, et al. Mapping intact protein isoforms in discovery mode using top-down proteomics. Nature. 2011;480:254–258.
   PubMed Web of Science ®Google Scholar
• Thakur SS, Geiger T, Chatterjee B, et al. Deep and highly sensitive proteome coverage by LC-MS/MS without prefractionation. Mol Cell Proteomics. 2011;10(8):M110.003699.
   PubMed Web of Science ®Google Scholar
• Durbin KR, Fornelli L, Fellers RT, et al. Quantitation and identification of thousands of human proteoforms below 30 kDa. J Proteome Res. 2016;15:976–982.
   PubMed Web of Science ®Google Scholar
• Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights. 2007;1:1–48.
   PubMedGoogle Scholar
• Parker CE, Borchers CH. Mass spectrometry based biomarker discovery, verification, and validation–quality assurance and control of protein biomarker assays. Mol Oncol. 2014;8:840–858.
   PubMed Web of Science ®Google Scholar
• Goossens N, Nakagawa S, Sun X, et al. Cancer biomarker discovery and validation. Transl Cancer Res. 2015;4:256–269.
   PubMed Web of Science ®Google Scholar
• Crutchfield CA, Thomas SN, Sokoll LJ, et al. Advances in mass spectrometry-based clinical biomarker discovery. Clin Proteomics. 2016;13:1.
   PubMed Web of Science ®Google Scholar
• Li J, Kelm KB, Tezak Z. Regulatory perspective on translating proteomic biomarkers to clinical diagnostics. J Proteomics. 2011;74:2682–2690.
   PubMed Web of Science ®Google Scholar
• Füzéry AK, Levin J, Chan MM, et al. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics. 2013;10:13.
   PubMed Web of Science ®Google Scholar
• Skates SJ, Gillette MA, LaBaer J, et al. Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. J Proteome Res. 2013;12:5383–5394.
   PubMed Web of Science ®Google Scholar
• Drucker E, Krapfenbauer K. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. Epma J. 2013;4:7.
   PubMedGoogle Scholar
• Hernández B, Parnell A, Pennington SR. Why have so few proteomic biomarkers “survived” validation? (sample size and independent validation considerations). Proteomics. 2014;14:1587–1592.
   PubMed Web of Science ®Google Scholar
• Su F, Lang J, Kumar A, et al. Validation of candidate serum ovarian cancer biomarkers for early detection. Biomark Insights. 2007;2:369–375.
   PubMedGoogle Scholar
• Longoria TC, Ueland FR, Zhang Z, et al. Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer. Am J Obstet Gynecol. 2014;210:78.e71-9.
   PubMed Web of Science ®Google Scholar
• Drabovich AP, Martínez-Morillo E, Diamandis EP. Toward an integrated pipeline for protein biomarker development. Biochim Biophys Acta. 2015;1854:677–686.
   PubMed Web of Science ®Google Scholar
• Frantzi M, Bhat A, Latosinska A. Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clin Transl Med. 2014;3:7.
   PubMedGoogle Scholar
• Tageja N. Bridging the translation gap - new hopes, new challenges. Fundam Clin Pharmacol. 2011;25:163–171.
   PubMed Web of Science ®Google Scholar
• Sallam RM. Proteomics in cancer biomarkers discovery: challenges and applications. Dis Markers. 2015;321370:2015.
   Google Scholar
• Public workshop - mass spectrometry in the clinic: Regulatory considerations surrounding validation of liquid chromatography-mass spectrometry based devices. (US Food and Drug Administration, May 2, 2016) Available from: http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm486484.htm
   Google Scholar
• Lacey JM, Bergen HR, Magera MJ, et al. Rapid determination of transferrin isoforms by immunoaffinity liquid chromatography and electrospray mass spectrometry. Clin Chem. 2001;47:513–518.
   PubMed Web of Science ®Google Scholar
• Bergen HR, Zeldenrust SR, Butz ML, et al. Identification of transthyretin variants by sequential proteomic and genomic analysis. Clin Chem. 2004;50:1544–1552.
   PubMed Web of Science ®Google Scholar
• Zanella-Cleon I, Joly P, Becchi M, et al. Phenotype determination of hemoglobinopathies by mass spectrometry. Clin Biochem. 2009;42:1807–1817.
   PubMed Web of Science ®Google Scholar
• Gregorc V, Novello S, Lazzari C, et al. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. Lancet Oncol. 2014;15:713–721.
   PubMed Web of Science ®Google Scholar
• Trenchevska O, Nedelkov D. Targeted quantitative mass spectrometric immunoassay for human protein variants. Proteome Sci. 2009;9:19.
   Web of Science ®Google Scholar
• Trenchevska O, Kamcheva E, Nedelkov D. Mass spectrometric immunoassay for quantitative determination of protein biomarker isoforms. J Proteome Res. 2010;9:5969–5973.
   PubMed Web of Science ®Google Scholar
• Kiernan UA, Phillips DA, Trenchevska O, et al. Quantitative mass spectrometry evaluation of human retinol binding protein 4 and related variants. PLoS One. 2011;6:e17282.
   PubMed Web of Science ®Google Scholar
• Bystrom CE, Salameh W, Reitz R, et al. Plasma renin activity by LC-MS/MS: development of a prototypical clinical assay reveals a subpopulation of human plasma samples with substantial peptidase activity. Clin Chem. 2010;56:1561–1569.
   PubMed Web of Science ®Google Scholar
• Bystrom C, Sheng S, Zhang K, et al. Clinical utility of insulin-like growth factor 1 and 2; determination by high resolution mass spectrometry. PLoS One. 2012;7:e43457.
   PubMedGoogle Scholar
• Chen Z, Caulfield MP, McPhaul MJ, et al. Quantitative insulin analysis using liquid chromatography-tandem mass spectrometry in a high-throughput clinical laboratory. Clin Chem. 2013;59:1349–1356.
   PubMed Web of Science ®Google Scholar
• Vachani A, Pass HI, Rom WN, et al. Validation of a multiprotein plasma classifier to identify benign lung nodules. J Thorac Oncol. 2015;10:629–637.
   PubMed Web of Science ®Google Scholar
• Hoofnagle AN, Roth MY. Clinical review: improving the measurement of serum thyroglobulin with mass spectrometry. J Clin Endocrinol Metab. 2013;98:1343–1352.
   PubMed Web of Science ®Google Scholar
• Kushnir MM, Rockwood AL, Strathmann FG, et al. LC-MS/MS measurement of parathyroid hormone-related peptide. Clin Chem. 2016;62:218–226.
   PubMed Web of Science ®Google Scholar
• Saade GR, Boggess KA, Sullivan SA, et al. Development and validation of a spontaneous preterm delivery predictor in asymptomatic women. Am J Obstet Gynecol. 2016;214:633.e631-633.e624.
   Web of Science ®Google Scholar
• La Marca G. Mass spectrometry in clinical chemistry: the case of newborn screening. J Pharm Biomed Anal. 2014;101:174–182.
   PubMed Web of Science ®Google Scholar
• Smith LM, Kelleher NL. Proteomics CfTD. Proteoform: a single term describing protein complexity. Nat Methods. 2013;10:186–187.
   PubMed Web of Science ®Google Scholar
• Toby TK, Fornelli L, Kelleher NL. Progress in top-down proteomics and the analysis of proteoforms. Annu Rev Anal Chem (Palo Alto Calif). 2016;9:499–519.
   PubMed Web of Science ®Google Scholar
• Marquette CA, Corgier BP, Blum LJ. Recent advances in multiplex immunoassays. Bioanalysis. 2012;4:927–936.
   PubMed Web of Science ®Google Scholar
• Lenters-Westra E, Schindhelm RK, Bilo HJ, et al. Haemoglobin A1c: historical overview and current concepts. Diabetes Res Clin Pract. 2013;99:75–84.
   PubMed Web of Science ®Google Scholar
• Jeppsson JO, Kobold U, Barr J, et al. Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med. 2002;40:78–89.
   PubMed Web of Science ®Google Scholar
• Little RR, Sacks DB. HbA1c: how do we measure it and what does it mean? Curr Opin Endocrinol Diabetes Obes. 2009;16:113–118.
   PubMed Web of Science ®Google Scholar
• Jones JJ, Wilcox BE, Benz RW, et al. A plasma-based protein marker panel for colorectal cancer detection identified by multiplex targeted mass spectrometry. Clin Colorectal Cancer. 2016;15:186–94.e113.
   PubMed Web of Science ®Google Scholar
• Yassine HN, Jackson AM, Reaven PD, et al. The application of multiple reaction monitoring to assess apo a-i methionine oxidations in diabetes and cardiovascular disease. Transl Proteom. 2014;4-5:18–24.
   PubMedGoogle Scholar
• Yassine HN, Trenchevska O, He H, et al. Serum amyloid a truncations in type 2 diabetes mellitus. PLoS One. 2015;10:e0115320.
   PubMed Web of Science ®Google Scholar
• Yassine HN, Trenchevska O, Ramrakhiani A, et al. The association of human apolipoprotein C-III sialylation proteoforms with plasma triglycerides. PLoS One. 2015;10:e0144138.
   PubMed Web of Science ®Google Scholar
• Yassine HN, Trenchevska O, Dong Z, et al. The association of plasma cystatin C proteoforms with diabetic chronic kidney disease. Proteome Sci. 2016;14:7.
   PubMed Web of Science ®Google Scholar
• Koska J, Yassine H, Trenchevska O, et al. Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes. J Lipid Res. 2016;57:894–905.
   PubMed Web of Science ®Google Scholar
• Cheng K, Chui H, Domish L, et al. Recent development of mass spectrometry and proteomics applications in identification and typing of bacteria. Proteomics Clin Appl. 2016;10:346–357.
   PubMed Web of Science ®Google Scholar
• Annesley T, Diamandis E, Bachmann L, et al. A spectrum of views on clinical mass spectrometry. Clin Chem. 2016;62:30–36.
   PubMed Web of Science ®Google Scholar
• Mischak H. How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS. Proteomics Clin Appl. 2012;6:437–442.
   PubMed Web of Science ®Google Scholar
• Stepczynska A, Schanstra JP, Mischak H. Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management. Bioanalysis. 2016;8:439–455.
   PubMed Web of Science ®Google Scholar
• Duncan MW, Nedelkov D, Walsh R, et al. Applications of MALDI mass spectrometry in clinical chemistry. Clin Chem. 2016;62:134–143.
   PubMed Web of Science ®Google Scholar
• Ferreira CR, Yannell KE, Jarmusch AK, et al. Ambient ionization mass spectrometry for point-of-care diagnostics and other clinical measurements. Clin Chem. 2016;62:99–110.
   PubMed Web of Science ®Google Scholar
• Abbatiello SE, Schilling B, Mani DR, et al. Large-scale interlaboratory study to develop, analytically validate and apply highly multiplexed, quantitative peptide assays to measure cancer-relevant proteins in plasma. Mol Cell Proteomics. 2015;14:2357–2374.
   PubMed Web of Science ®Google Scholar
• Carr SA, Abbatiello SE, Ackermann BL, et al. Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics. 2014;13:907–917.
   PubMed Web of Science ®Google Scholar
• Nelson RW, Borges CR. Mass spectrometric immunoassay revisited. J Am Soc Mass Spectrom. 2011;22:960–968.
   PubMed Web of Science ®Google Scholar
• Nedelkov D. Mass spectrometry-based protein assays for in vitro diagnostic testing. Expert Rev Mol Diagn. 2012;12:235–239.
   PubMed Web of Science ®Google Scholar
• Carbone DP, Ding K, Roder H, et al. Prognostic and predictive role of the veriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC clinical trials group BR.21 trial. J Thorac Oncol. 2012;7:1653–1660.
   PubMed Web of Science ®Google Scholar
• Pant Pai N, Balram B, Shivkumar S, et al. Head-to-head comparison of accuracy of a rapid point-of-care HIV test with oral versus whole-blood specimens: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:373–380.
   PubMed Web of Science ®Google Scholar
• Boja ES, Fehniger TE, Baker MS, et al. Analytical validation considerations of multiplex mass-spectrometry-based proteomic platforms for measuring protein biomarkers. J Proteome Res. 2014;13:5325–5332.
   PubMed Web of Science ®Google Scholar
• Duggan JX, Vazvaei F, Jenkins R. Bioanalytical method validation considerations for LC-MS/MS assays of therapeutic proteins. Bioanalysis. 2015;7:1389–1395.
   PubMed Web of Science ®Google Scholar
• Lathrop JT, Jeffery DA, Shea YR, et al. US food and drug administration perspectives on clinical mass spectrometry. Clin Chem. 2016;62:41–47.
   PubMed Web of Science ®Google Scholar
• VITEK®MS System: A mass spectrometer system using matrix-assisted laser desorption/ionization - time to flight (MALDI-TOF) for the identification of microorganisms cultured from human specimens. (US FDA, 08/21/2013) http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?ID=DEN130013
   Google Scholar
• MALDI Biotyper CA System: Qualitative in vitro diagnostic device intended for identification of gram-negative bacterial colonies cultured from human specimens. (US FDA, 11/21/2013) https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K130831
   Google Scholar
• Lequin RM. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). Clin Chem. 2005;51:2415–2418.
   PubMed Web of Science ®Google Scholar
• Nedelkov D. Mass spectrometry-based immunoassays for the next phase of clinical applications. Expert Rev Proteomics. 2006;3:631–640.
   PubMed Web of Science ®Google Scholar